Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)

Blood Pressure Clinical Trial

Official title:

Randomized, Placebo-Controlled, Double-Blind, Two-Way Crossover Study to Evaluate the Effects of Phenylephrine HCl Extended-Release Tablets 30 mg Compared to Placebo on Ambulatory Blood Pressure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00874120
• Other study ID #: 18121
• Secondary ID: CL2007-07P07529
• Status: Completed
• Phase: Phase 3
• First received: April 1, 2009
• Last updated: February 20, 2015
• Start date: December 2008
• Est. completion date: February 2009

Study information

• Verified date: February 2015
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, placebo-controlled double-blind, crossover design study; 116 subjects randomized on Day 1 to obtain 98 completed subjects. Study will be composed of a 7-day period of therapy with randomized active or placebo treatment with a subsequent 6-8 day washout period, followed by a second 7-day period of double-blind therapy with the other agent. Ambulatory blood pressure measurement will be performed beginning on Day 7 of each treatment period following administration of the study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 116
• Est. completion date: February 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy, male or female volunteers must be 18 years or older, with a Body Mass Index (BMI) between 19-30 inclusive [BMI = weight (kilograms)/height (meters squared)].

• Clinical laboratory tests (complete blood count, blood chemistries, urinalysis), Human Immunodeficiency Virus (HIV) antibodies, hepatitis B surface antigen, hepatitis C antibody must be within normal limits or clinically acceptable to the Investigator/Sponsor.

• Drug screen for drugs and alcohol with a high potential for abuse must be negative at screening.

• Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations, procedures or participation.

• Subjects must agree not to take a monoamine oxidase inhibitor (MAOI) for two weeks (14 days) prior to study participation and for two weeks (14 days) after the end of their study participation.

• Subjects must have normal or clinically acceptable physical exam and Electrocardiogram (ECG) intervals (PR, QRS, QT and QTc) on 12-lead ECG (recorded at 25 millimeters/second [mm/s]).

• Subjects must have a mean after 5 minute of rest sitting systolic/diastolic office blood pressure = 138/88 millimeters of mercury (mmHg).

• Subjects with controlled diabetes prior to entry must have a mean sitting after 5 minute of rest systolic/diastolic office blood pressure = 128/78 mmHg from non-dominated arm

• Females must have the urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1 of Period 1.

• Female subjects of childbearing potential must be using medically acceptable birth control measures.

• Subjects must understand the dosing schedule.

• Subjects must be able to read and write in English.

Exclusion Criteria:

• Subjects must not have any significant medical condition which, in the judgment of the Investigator, is a contraindication to the use of phenylephrine HCl, might interfere with the study or requires treatment expected to affect the blood pressure. These may include hyperthyroidism, hypothyroidism, uncontrolled diabetes mellitus, coronary heart disease, ischemic heart disease, elevated intraocular pressure, prostatic hypertrophy.

• Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration.

• Subjects who have received an investigational drug within 30 days prior to study dosing.

• Subjects who are, appear to be, or are known, current or former drug addicts or alcoholics.

• Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody.

• Subjects who are positive for HIV antibodies.

• Subjects who have a clinically significant history of food or drug allergy.

• Subjects who have a known allergy or intolerance to phenylephrine HCl.

• Females who are pregnant, nursing or unwilling to use/practice adequate contraception (hormonal, Intrauterine Device, barrier method, etc.).

• Subjects taking topical or oral decongestant products within 7 days of Visit 2.

• Subjects taking antihypertensive medication.

• Subjects taking monoamine oxidase inhibitors.

• Subjects taking tricyclic antidepressants (e.g. amitriptyline, nortriptyline, imipramine)

• Subjects taking antithyroid medication (e.g. propylthiouracil, methimazole, iodides).

Related Conditions & MeSH terms

• Blood Pressure
• Human Experimentation

Intervention

Drug:
• Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg
Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
• Placebo
Placebo taken twice daily (12 hours apart) for 7 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).	Five hour (hr) range around the Tmax was defined as approximately 2 hours before to approximately 2 hours after the Tmax, including Tmax. The parameters will be compared between active drug and placebo using analysis of variance (ANOVA). The 95% 2-sided Confidence Interval (CI) on the difference between treatments will also be presented.	24 hours after final dose of each 7-day treatment period.